-
Development and Validation of Coding Algorithms to Identify Patients with Incident Non-Small Cell Lung Cancer in United States Healthcare Claims Data
12 Jan 2023 04:31 GMT
… adults.3 Lung cancer is a heterogenous disease. Most lung cancers in the … (incident) small-cell lung cancer (SCLC) and other lung cancers, a 5% random sample … this time period [cyclophosphamide, doxorubicin, irinotecan, vincristine, or topotecan]) for …
-
Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases
13 Dec 2022 23:43 GMT
… lung cancer is classified as small cell lung cancer (SCLC) or non–small cell lung cancer … small cell lung cancer: consequences … irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer … -cell lung cancer. Clin Lung Cancer. 2008 …
-
Episode 5: Small Cell Lung Cancer Treatment Options
15 Nov 2022 14:43 GMT
… included, tend to use irinotecan rather than topotecan. Aside … these different small cell lung cancers. They look different … small cell lung cancer, we subtype small cell lung cancer into … Lung Cancer
Testing Maintenance Therapy for Small Cell Lung Cancer …
-
RRx-001 + Irinotecan Significantly Improved Progression Free Survival (PFS) Versus Regorafenib in the Randomized Phase 2 ROCKET Trial in Advanced Colorectal Cancer
14 Dec 2022 16:48 GMT
… , RRx-001, plus irinotecan versus standard of care … that previously received the irinotecan-containing chemotherapy regimen, FOLFIRI … treatment of small cell lung cancer (SCLC), and in … releases/rrx-001--irinotecan-significantly-improved-progression-free …
-
Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment
17 Oct 2022 21:28 GMT
… lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases. About 30% of lung cancer … patients are locally advanced lung cancer … cell lung cancer. Transl Lung Cancer Res. … , and irinotecan versus topotecan …
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
11 Sep 2022 16:04 GMT
… 3 weeks or either irinotecan (N=55) 150 mg … improvements for people with lung cancer, including and beyond treatment … Patients With HER2-Mutant Lung Cancers. Cancer. 2019;125: … with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed …
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
11 Sep 2022 13:53 GMT
… 3 weeks or either irinotecan (N=55) 150 mg … improvements for people with lung cancer, including and beyond treatment … Patients With HER2-Mutant Lung Cancers. Cancer. 2019;125: … with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed …
-
ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer
11 Sep 2022 09:56 GMT
… metastatic non-small cell lung cancer and further demonstrates that … mutant non-small cell lung cancer, reinforces the potential to … every 3 weeks or either irinotecan (N=55) 150 mg …
2 American Cancer Society. Lung Cancer Survival Rates. Accessed September …
-
ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer
11 Sep 2022 09:29 GMT
… metastatic non-small cell lung cancer and further demonstrates that … in patients diagnosed with lung cancer.”
All patients in DESTINY … every 3 weeks or either irinotecan (N=55) 150 mg …
2 American Cancer Society. Lung Cancer Survival Rates. Accessed September …
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
12 Aug 2022 11:21 GMT
… detect HER2 mutations in lung tumor tissue and plasma. This … every 3 weeks or either irinotecan (N=55) 150 mg… meaningful improvements for people with lung cancer, including and beyond treatment. … in Patients With HER2-Mutant Lung Cancers. Cancer. 2019;125: …